S-Editor Sun YLL-Editor Table 1 Adverse effects of pancreatic cryosurgery
Adverse effects |
n of patients |
％ |
Abdominal pain |
34 |
69.4 |
Fever |
26 |
53.1 |
Acute pancreatitis* |
6 |
12.2 |
Increased amylase levels** |
25 |
51.0 |
Abdominal bleeding*** |
3 |
6.1 |
Pulmonary infection |
3 |
6.1 |
Myocardial infarction |
1 |
2.0 |
Cerebral infarction |
1 |
2.0 |
* with abdominal pain and fever，** including 6 patients with acute pancreatitis，*** with abdominal pain
Table 2 Lok-rank test for univariate analysis of prognostic factors in 49 patients with locally advanced pancreatic cancer
Prognostic factors |
Patient subgroups |
n |
Median survival
(mo) |
p |
Tumor size |
</=4cm
>4cm |
24
25 |
13
14 |
0.6254 |
Tumor location |
head
body or tail |
15
34 |
22
12 |
0.0204 |
Mode of
cryosurgery |
intra-operative
percutaneous |
13
36 |
11
14 |
0.4558 |
Adjuvant
chemotherapy |
yes
no |
20
29 |
11
22 |
0.0003 |
Hepatic
metastases |
yes
no |
12
37 |
11
19 |
0.0010 |
Table 3Median survival in different subgroups of patients with pancreatic cancer
Patient subgroups |
n |
Median survival (mon) |
P |
Tumor location cancer |
|
|
pancreatic head |
15 |
22 |
0.0204 |
pancreatic body or tail |
34 |
12 |
Tumor size |
|
|
|
</＝4cm |
24 |
13 |
>0.6 |
>4cm |
25 |
14 |
Mode of cryosurgery |
|
|
>0.1
|
Inoperative |
13 |
11 |
Percutaneous |
36 |
14 |
Adjuvant chemotherapy |
|
|
<0.0003 |
Yes |
20 |
11 |
No |
29 |
22 |
|
Hepatic metastases |
|
|
<0.01 |
Yes |
12 |
11 |
No |
37 |
19 |
|
Table 4Recent chemoradiation trials in pantients with locally advanced pancreatic cancer
Reporter |
n of patients |
Therapy |
Median progressive-free survival(mos) |
Median survival (mo) |
Objective response % |
Survival at 12 mo after treatment% |
El-Rayer[25] |
47 |
gemcitabine,cisplatin,and infusional fluorouracil |
|
|
|
34 |
Tokuuye[26] |
53 |
Small-field radiotherapy in combination with concomitant chemotherapy
|
|
10.2 |
|
35.2 |
Okusaka[27] |
34 |
gemcitabine+5-FU |
3.2 |
7.1 |
25 |
14.3 |
Yamazaki[28] |
22 |
Concurrent Chemoradiotherapygemcitabine |
|
16 |
32 |
78 |
Isacoff[29] |
50 |
5-FU,mitomycin dipyridamore |
|
|
26 |
54 |
Park[30] |
45 |
gemcitabine＋capecitabine |
5.4 |
10.4 |
40 |
|
Ko[31] |
25 |
Gemcitabine+cisplatin,re-radiation+ capecitabine |
10.5 |
13.5 |
|
62 |
Polyzos[32] |
32 |
gemcitabine＋5－FU，folic acid,somostatin |
7 |
7 |
22 |
20 |
Michael[33] |
30 |
gemcitabine＋13－cis |
|
7.8 |
|
|
Furuse[34] |
|
Intraoperative radiation, 5－FU infusion |
|
7.8 |
|
8.1（2年） |
This series
|
38
|
Cryosurgery and 125 iodine seed implantation
|
|
12
|
CR＋PR 59.2 |
63.1 |
A
B
Figure 1Survival rates of patients with pancreatic cancer.A:overall patients and patients with different location and size of tumor;B: pancreatic cancer with different modes of therapies, and with or without hepatic metastases
Figure 2Pancreatic CT scan in case 1.(A)before treatment.(B) three mo after treatment.(C)12 mo after treatment.
  
A B C
Figure 3CT scan of case 2.(A)before treatment, a mass was seen in pancreatic body and trail.(B) 0ne month after treatment.(C) 6 mo after treatment
 
A B
Figure 4CT scan in case 3. (A) before treatment. (B)Three mo after treatment
Figure 5CT scan in case 4. (A) before treatment. (B)during treatment.(C) 8 mo after treatment
A |
B |
Figure 6CT scan in case 5. (A) before treatment. (B)6 mo after treatment
igure 7 CT and PET-CT in case 6.（A）CT before treatment.（B）PET-CT at 12 mo after the first treatment.(C) PET-CT at 3 mo after second treatment
|
